Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients

Karin Yaacoby-Bianu, Michal Gur, Yazeed Toukan, Vered Nir, Fahed Hakim, Yuval Geffen, Lea Bentur

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Background: Mycobacterium abscessus is one of the most antibiotic-resistant pathogens in cystic fibrosis (CF) patients. Nitric oxide (NO) has broad-spectrum antimicrobial activity. Clinical studies indicated that it is safe and tolerable when given as 160 ppm intermittent inhalations. Methods: A prospective compassionate adjunctive inhaled NO therapy in 2 CF patients with persistent Mycobacterium abscessus infection. Results: No adverse events were reported. Both subjects showed significant reduction in quantitative polymerase chain reaction results for Mycobacterium abscessus load in sputum during treatment; estimated colony forming unit decreased from 7000 to 550 and from 3000 to 0 for patient 1 and patient 2, respectively. Conclusions: Intermittent inhalations with 160 ppm NO are well tolerated, safe and result in significant reduction of Mycobacterium abscessus load. It may constitute an adjuvant therapeutic approach for CF patients with Mycobacterium abscessus lung disease. Further studies are needed to define dosing, duration and long-term clinical outcome.

Original languageEnglish
Pages (from-to)336-338
Number of pages3
JournalPediatric Infectious Disease Journal
Issue number4
StatePublished - 1 Apr 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.


  • Mycobacterium abscessus complex infection
  • cystic fibrosis
  • nitric oxide


Dive into the research topics of 'Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients'. Together they form a unique fingerprint.

Cite this